267 related articles for article (PubMed ID: 9174680)
1. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man.
Flesch G; Müller P; Lloyd P
Eur J Clin Pharmacol; 1997; 52(2):115-20. PubMed ID: 9174680
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose.
Waldmeier F; Flesch G; Müller P; Winkler T; Kriemler HP; Bühlmayer P; De Gasparo M
Xenobiotica; 1997 Jan; 27(1):59-71. PubMed ID: 9041679
[TBL] [Abstract][Full Text] [Related]
3. An interaction study with cimetidine and the new angiotensin II antagonist valsartan.
Schmidt EK; Antonin KH; Flesch G; Racine-Poon A
Eur J Clin Pharmacol; 1998 Feb; 53(6):451-8. PubMed ID: 9551704
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects.
Müller P; Flesch G; de Gasparo M; Gasparini M; Howald H
Eur J Clin Pharmacol; 1997; 52(6):441-9. PubMed ID: 9342579
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
Czendlik CH; Sioufi A; Preiswerk G; Howald H
Eur J Clin Pharmacol; 1997; 52(6):451-9. PubMed ID: 9342580
[TBL] [Abstract][Full Text] [Related]
6. High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method.
Daneshtalab N; Lewanczuk RZ; Jamali F
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Jan; 766(2):345-9. PubMed ID: 11824822
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide.
Bindschedler M; Degen P; Flesch G; de Gasparo M; Preiswerk G
Eur J Clin Pharmacol; 1997; 52(5):371-8. PubMed ID: 9272406
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence study of a valsartan tablet and a capsule formulation after single dosing in healthy volunteers using a replicated crossover design.
Séchaud R; Graf P; Bigler H; Gruendl E; Letzkus M; Merz M
Int J Clin Pharmacol Ther; 2002 Jan; 40(1):35-40. PubMed ID: 11837381
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers.
Iqbal M; Khuroo A; Batolar LS; Tandon M; Monif T; Sharma PL
Clin Ther; 2010 Mar; 32(3):588-96. PubMed ID: 20399995
[TBL] [Abstract][Full Text] [Related]
10. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
Belz GG; Butzer R; Kober S; Mang C; Mutschler E
Clin Pharmacol Ther; 1999 Oct; 66(4):367-73. PubMed ID: 10546920
[TBL] [Abstract][Full Text] [Related]
11. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of multiple doses of valsartan in patients with heart failure.
Prasad PP; Yeh CM; Gurrieri P; Glazer R; McLeod J
J Cardiovasc Pharmacol; 2002 Nov; 40(5):801-7. PubMed ID: 12409989
[TBL] [Abstract][Full Text] [Related]
13. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y
Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545
[TBL] [Abstract][Full Text] [Related]
14. The effect of age on the pharmacokinetics of valsartan.
Sioufi A; Marfil F; Jaouen A; Cardot JM; Godbillon J; Ezzet F; Lloyd P
Biopharm Drug Dispos; 1998 May; 19(4):237-44. PubMed ID: 9604123
[TBL] [Abstract][Full Text] [Related]
15. Valsartan: a novel angiotensin type 1 receptor antagonist.
Thürmann PA
Expert Opin Pharmacother; 2000 Jan; 1(2):337-50. PubMed ID: 11249553
[TBL] [Abstract][Full Text] [Related]
16. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of valsartan in patients with liver disease.
Brookman LJ; Rolan PE; Benjamin IS; Palmer KR; Wyld PJ; Lloyd P; Flesch G; Waldmeier F; Sioufi A; Mullins F
Clin Pharmacol Ther; 1997 Sep; 62(3):272-8. PubMed ID: 9333102
[TBL] [Abstract][Full Text] [Related]
18. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
Spínola AC; Almeida S; Filipe A; Neves R; Trabelsi F; Farré A
Clin Ther; 2009 Sep; 31(9):1992-2001. PubMed ID: 19843489
[TBL] [Abstract][Full Text] [Related]
19. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
White WB; Lacourciere Y; Davidai G
Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects.
Müller P; Cohen T; de Gasparo M; Sioufi A; Racine-Poon A; Howald H
Eur J Clin Pharmacol; 1994; 47(3):231-45. PubMed ID: 7867676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
